Home/Investors/Medicxi

Medicxi

Biotech Investor · 8 portfolio companies

Portfolio

8

Combined Value

$6.1B

Focus Areas

15

Top Stage

Phase 2

Investment Focus

Neuroscience Oncology Respiratory Infectious Disease Immuno-Dermatology Dermatology Inflammatory Skin Diseases Neurology Neuropsychiatry Rare Vascular Diseases Hereditary Hemorrhagic Telangiectasia (HHT)Chronic Pain Osteoarthritis Metabolic Cardiovascular

Portfolio Companies

Company	Stage	Valuation	Focus
Centessa Pharmaceuticals	Phase 2	$6.1B	Neuroscience, Oncology
Pheon Therapeutics	preclinical	—	Oncology
Altesa BioSciences	Phase 2	—	Respiratory, Infectious Disease
Alys Pharmaceuticals	Phase 1	—	Immuno-Dermatology, Dermatology
Noema Pharma	Phase 2	—	Neurology, Neuropsychiatry
Vaderis Therapeutics	Pre-clinical	—	Rare Vascular Diseases, Hereditary Hemorrhagic Telangiectasia (HHT)
Levicept	Phase 2	—	Chronic Pain, Osteoarthritis
Epetome	phase-1	—	Metabolic, Cardiovascular

Frequent Co-Investors

Forbion2 shared Atlas Venture1 shared Droia Ventures1 shared Pitango1 shared Abingworth1 shared Jeito Capital1 shared TVM Capital Life Science1 shared General Atlantic1 shared